Apogee CFO sells 2,000 shares under 10b5-1 plan

Apogee Therapeutics Chief Financial Officer Jane Henderson reported selling 2,000 shares of Apogee Therapeutics common stock in a series of open-market transactions on March 2, 2026.

Rhea-AI Filing Summary

Apogee Therapeutics Chief Financial Officer Jane Henderson reported selling 2,000 shares of Apogee Therapeutics common stock in a series of open-market transactions on March 2, 2026. The sales, coded as open-market transactions, occurred at weighted average prices of $68.27, $69.43, $70.45 and $71.66, with each price reflecting multiple trades within stated ranges. These transactions were carried out under a Rule 10b5-1 trading plan adopted on September 2, 2025. After the final sale, Henderson directly held 181,371 shares of Apogee Therapeutics common stock.

Insider Trade Summary

Net Seller: 2,000 shares

Net Sell 4 txns

Insider Henderson Jane

Role Chief Financial Officer

Sold 2,000 shs ($140K)

Type	Security	Shares	Price	Value
Sale	Common Stock	300	$68.27	$20K
Sale	Common Stock	300	$69.43	$21K
Sale	Common Stock	994	$70.45	$70K
Sale	Common Stock	406	$71.66	$29K

Holdings After Transaction: Common Stock — 181,371 shares (Direct)

Footnotes (5)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.
2. F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.77 to $68.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.91 to $69.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
4. F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.03 to $70.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
5. F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.04 to $71.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

FAQ

What insider transaction did Apogee Therapeutics (APGE) report for Jane Henderson?

Apogee Therapeutics reported that CFO Jane Henderson sold 2,000 shares of common stock in four open-market transactions on March 2, 2026. All trades involved Apogee Therapeutics common shares and were reported on a Form 4 filing.

At what prices did the Apogee Therapeutics (APGE) CFO sell her shares?

The CFO’s sales used weighted average prices of $68.27, $69.43, $70.45, and $71.66. Each reported price reflects multiple trades within specified ranges, as detailed in the Form 4 footnotes for these open-market transactions.

How many Apogee Therapeutics (APGE) shares does the CFO hold after the sale?

Following the March 2, 2026 transactions, CFO Jane Henderson directly holds 181,371 shares of Apogee Therapeutics common stock. This post-transaction holding is reported in the Form 4 as the total shares beneficially owned after the final sale.

Was the Apogee Therapeutics (APGE) CFO stock sale under a Rule 10b5-1 plan?

Yes. The Form 4 states the transaction was executed under a Rule 10b5-1 trading plan adopted on September 2, 2025. Such plans pre-schedule trades, allowing insiders to systematically sell shares according to predetermined instructions.

What type of transactions did Apogee Therapeutics (APGE) disclose for its CFO?

The company disclosed open-market sales of common stock by its CFO, classified with transaction code “S.” All four transactions on March 2, 2026 are non-derivative, direct ownership sales reported as open-market or private transactions.

How many total shares did the Apogee Therapeutics (APGE) CFO sell in this Form 4?

According to the Form 4 transaction summary, CFO Jane Henderson sold 2,000 shares of Apogee Therapeutics common stock. The filing lists four separate non-derivative sale entries that together make up this total net sell amount.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Henderson Jane

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		300	D	$68.27(2)	183,071	D
Common Stock	03/02/2026		S(1)		300	D	$69.43(3)	182,771	D
Common Stock	03/02/2026		S(1)		994	D	$70.45(4)	181,777	D
Common Stock	03/02/2026		S(1)		406	D	$71.66(5)	181,371	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.77 to $68.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.91 to $69.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.03 to $70.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.04 to $71.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Matthew Batters, as attorney-in-fact for Jane Pritchett Henderson	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.